Liquid Raises $700K Pre-

Vaxine Pty Ltd

Vaxine Pty Ltd is a rapidly growing Australian biotechnology company based in Adelaide that has developed an impressive pipeline of vaccines against infectious disease, allergy, and cancer . Vaxine has developed the Advax range of proprietary polysaccharide adjuvants and is currently applying this state of the art adjuvant technology to development of vaccines against hepatitis B, pandemic influenza, Japanese encephalitis, West Nile virus, malaria, HIV and rabies, amongst others.

Piche Resources (ASX:PR2)

Piche Resources Limited (ASX: PR2) is a mineral exploration company focussed on uranium, precious metals, and other critical metals in Western Australia (WA) and Argentina. The Company has a unique portfolio of potentially large-scale, high value projects targeted for rapid exploration and development, including four Australian projects and two Argentinian projects. Over the immediate term, Piche's strategy is to complete three significant exploration and drilling campaigns on the Ashburton uranium project in WA, and at Sierra Cuadrada uranium and Cerro Chacon gold projects in Argentina. Longer term, Piche aims to build a significant mining group with separate uranium, gold, and base metal companies under its banner, capitalising on an improving commodity market.

OD6 Metals

OD6 Metals is an Australian public company with a purpose to pursue exploration and development opportunities within the resources sector. The Company holds a 100% interest in the Splinter Rock Project and Grass Patch Project which are located in the Goldfields-Esperance region of Western Australia, about 30 to 150km north of the major port and town of Esperance.

Immutep Limited

Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. Its lead clinical candidate in oncology is eftilagimod alfa, a proprietary soluble LAG-3 protein and MHC Class II agonist that activates the immune system to fight cancer. In autoimmune diseases, Immutep's IMP761 is the world's first LAG-3 agonist antibody designed to target the underlying causes of autoimmune diseases. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. For more information, please visit www.immutep.com.